Core Insights - The company reported a revenue of 745 million yuan for the first half of 2025, representing a year-on-year growth of 10.19% [1] - The net profit attributable to shareholders reached 121 million yuan, with a year-on-year increase of 14.17% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 118 million yuan, reflecting a year-on-year growth of 16.42% [1] - Basic earnings per share stood at 0.41 yuan [1] Revenue Breakdown - The main business revenue was 731 million yuan, showing a year-on-year increase of 10.35% [1] - Revenue from anesthesia products was 209 million yuan, down 4.79% year-on-year [1] - Revenue from catheter products was 220 million yuan, up 13.62% year-on-year [1] - Revenue from urology products reached 134 million yuan, marking a significant year-on-year growth of 43.90% [1] - Revenue from nursing products was 92 million yuan, with a year-on-year increase of 30.28% [1] - Revenue from blood purification products was 40 million yuan, reflecting a year-on-year growth of 18.44% [1] - Revenue from respiratory products was 27 million yuan, down 38.54% year-on-year [1]
维力医疗(603309.SH)发布上半年业绩 归母净利润1.21亿元 同比增长14.17%